Background Previous reviews have evaluated economic analyses of lipid-lowering therapies using lipid levels as surrogate markers for cardiovascular disease. However, drug approval and health technology assessment agencies have stressed that surrogates should only be used in the absence of clinical endpoints.Objective The aim of this systematic review was to identify and summarise the methodologies, weaknesses and strengths of economic models based on atherosclerotic cardiovascular disease event rates.Methods Cost-effectiveness evaluations of lipid-lowering therapies using cardiovascular event rates in adults with hyperlipidaemia were sought in Medline, Embase, Medline In-Process, PubMed and NHS EED and conference proceedings. Search results...
textabstractBackground: While there is good evidence to show that behavioural and lifestyle interven...
Background: In the quest for public and private resources, prevention continues to face a difficult ...
For treatment decisions in clinical practice, group-level treatment effects need to be translated in...
Background Previous reviews have evaluated economic analyses of lipid-lowering therapies using lipid...
Background: The reported cost effectiveness of cardiovascular disease management programs (CVD-MPs) ...
BACKGROUND: Various lipid measurements in monitoring/screening programmes can be used, alone or in c...
Background. Cardiovascular disease (CVD) exhibits the most striking public health significance due t...
OBJECTIVE: To review research addressing the management of cholesterol in the prevention of coronary...
Background. Cardiovascular disease (CVD) exhibits the most striking public health significance due t...
Background: The reported cost effectiveness of cardiovascular disease management programs (CVD-MPs) ...
BACKGROUND: Lipid-lowering therapy is costly but effective at reducing coronary heart disease (CHD) ...
AbstractUse of surrogate measures of effectiveness in cost-effectiveness analyses requires the assum...
This study is an analysis using economic modelling of cardiovascular disease prevention in primary c...
OnlinePublAim: We aimed to assess the cost effectiveness of four different lipid-lowering strategies...
Health care decision makers are increasingly forced to identify and implement the options for potent...
textabstractBackground: While there is good evidence to show that behavioural and lifestyle interven...
Background: In the quest for public and private resources, prevention continues to face a difficult ...
For treatment decisions in clinical practice, group-level treatment effects need to be translated in...
Background Previous reviews have evaluated economic analyses of lipid-lowering therapies using lipid...
Background: The reported cost effectiveness of cardiovascular disease management programs (CVD-MPs) ...
BACKGROUND: Various lipid measurements in monitoring/screening programmes can be used, alone or in c...
Background. Cardiovascular disease (CVD) exhibits the most striking public health significance due t...
OBJECTIVE: To review research addressing the management of cholesterol in the prevention of coronary...
Background. Cardiovascular disease (CVD) exhibits the most striking public health significance due t...
Background: The reported cost effectiveness of cardiovascular disease management programs (CVD-MPs) ...
BACKGROUND: Lipid-lowering therapy is costly but effective at reducing coronary heart disease (CHD) ...
AbstractUse of surrogate measures of effectiveness in cost-effectiveness analyses requires the assum...
This study is an analysis using economic modelling of cardiovascular disease prevention in primary c...
OnlinePublAim: We aimed to assess the cost effectiveness of four different lipid-lowering strategies...
Health care decision makers are increasingly forced to identify and implement the options for potent...
textabstractBackground: While there is good evidence to show that behavioural and lifestyle interven...
Background: In the quest for public and private resources, prevention continues to face a difficult ...
For treatment decisions in clinical practice, group-level treatment effects need to be translated in...